logo.png
Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)
April 20, 2021 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLEStudy sponsored and funded by the National Institute of Allergy and Infectious Diseases through the Autoimmunity...
logo.png
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results
March 15, 2021 07:05 ET | Corbus Pharmaceuticals Holdings, Inc.
 ●Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021  ●Company focused on advancing in-house programs in metabolic diseases, fibrotic disorders, and cancer with...
logo.png
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021
March 08, 2021 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
•   Company to host conference call and webcast on Monday, March 15, 2021 at 8:30 a.m. ET Norwood, MA, March 08, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)...
logo.png
Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis
November 09, 2020 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Topline data remain as previously reportedPost-hoc analyses showed lenabasum treatment was associated with a benefit in lung function (forced vital capacity) in subjects on established background...
logo.png
Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020
October 23, 2020 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
As previously reported, lenabasum did not meet its primary efficacy endpoint in the studyLenabasum was well tolerated with no new safety findingsExploratory post-hoc analyses revealed unexpectedly low...
logo.png
Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020
October 21, 2020 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Preliminary baseline subject demographics and disease characteristics in a Phase 3 clinical trial of the safety and efficacy of lenabasum in dermatomyositis (DETERMINE)Cannabinoid receptor type 2...
logo.png
Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates
October 08, 2020 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Company is restructuring with the goal of extending cash runway to mid-2022Workforce to be reduced by 54%Company to focus on completing Phase 3 dermatomyositis study and advancing preclinical pipeline...
logo.png
Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
September 08, 2020 07:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Topline data showed no significant differences in the primary and secondary endpoints when comparing lenabasum to placebo, both added to background drug therapyUnprecedented improvement was observed...
logo.png
Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates
August 06, 2020 07:05 ET | Corbus Pharmaceuticals Holdings, Inc.
RESOLVE-1 Phase 3 study of lenabasum for treatment of systemic sclerosis on schedule for topline data this summerPhase 2b study of lenabasum for cystic fibrosis topline results on schedule in Q3...
logo.png
Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
August 05, 2020 09:25 ET | Corbus Pharmaceuticals Holdings, Inc.
12-month, double-blind, placebo-controlled, multi-national study enrolled 176 participantsTopline results expected in fourth quarter of 2021 Dermatomyositis is a rare, systemic autoimmune disease with...